
As US measles cases top 3600, Christina Madison, PharmD, explains how pharmacists can counter vaccine misinformation and rebuild trust.

Sabrina McCrear is an assistant editor for The American Journal of Managed Care® (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for The Center for Biosimilars, an AJMC® publication.
Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on LinkedIn.

As US measles cases top 3600, Christina Madison, PharmD, explains how pharmacists can counter vaccine misinformation and rebuild trust.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Gay and bisexual men make up 79.8% of new HIV diagnoses; Christina Madison, PharmD, on why trusted messengers matter.

Kevin Astle, PharmD, on how pharmacies can reach young men unaware of their HIV status and why step therapy limits PrEP.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine

Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.

Overlapping COVID-19 and flu symptoms make diagnosis hard, says Trinity Health's Tammy Lundstrom, who outlines prevention and vaccine guidance.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

A bioethicist explains why Kalshi's new FDA approval and clinical trial betting markets raise concerns about bias, herd behavior, and insider trading.

All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Keith Kaye, MD, MPH, explains how shorter antibiotic courses and optimized dosing help balance treatment efficacy against C. diff risk.

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient outcomes.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Jason Pogue, PharmD, breaks down which antibiotic classes carry the highest C. diff risk and why treatment duration matters just as much.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let Clostridioides difficile persist.

A Danish cohort study found 100% RSV vaccine effectiveness in COPD, but Jorgen Vestbo, MD, urges caution interpreting real-world results.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in fibrotic ILD.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Yet H. Khor, MD, PhD, explains why the CPFE index can't replace CT imaging but may help triage which patients need scans.

Francesca Puggioni, MD, explains how real-world registry data, like the EU-ADVANTAGE study, informs regulatory decisions on asthma biologics.

Jorgen Vestbo, MD, on the COPERNICOS trial results, long-term antibiotic use versus resistance concerns, and where COPD treatment is headed.